SOURCE-LINKED INTELLIGENCE

Innovative Nucleic Acids Technologies for Analysis, Detection and Treatment

CORDIS · observation · Publication date unknown

uch as cancer, infectious and rare diseases. Breakthrough technologies like genome editing tool CRISPR/Cas9, direct RNA sequencing, multi-omics analysis procedure for NAs analysis, bioinformatics and machine learning for data analysis, and targeted delivery systems based on lipid nanoparticles (LNPs) prove the increasing interest in NAs applicability. However, the full potential of NAs is yet to be unlocked, and the translation of NAs into clinical practice is still facing many methodological and technological limitations such as low detection sensitivity, limited sequencing capacity, lack of analytical methods for NAs therapeutics, and inadequate in vivo delivery. INT2ACT brings together 6 academic research units and 5 industrial partners to address these limitations by establishing new methods for detecting and analysing NAs in patient liquid biopsies, boosting available procedures for direct RNA sequencing, developing new methods for the synthesis and analysis of antisense oligonucleotides (ASO) libraries, identifying new RNA targets, and optimise NA therapeutics delivery systems.

Read original source ↗ Open in workspace

recordType

award

status

SIGNED

region

EU

value

4533813

unit

EUR